Actively Recruiting
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
Led by Eli Lilly and Company · Updated on 2026-04-20
144
Participants Needed
3
Research Sites
61 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
CONDITIONS
Official Title
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age is 21-65 years old at Singapore Sites
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
- Part A: Body Mass Index (BMI) within the range greater than or equal to 21 and less than 30 kilogram per square meter (kg/m²)
- Part B: a BMI greater than or equal to 27 and less than 45 kg/m²
- Part C: a BMI greater than or equal to 21 and less than 35 kg/m²
- Parts A and C: Participants must weigh 60 kilograms (kg) or more at screening
- Have had a less than 5% change in body weight for 3 months before screening
- Safety laboratory tests are within normal reference range
You will not qualify if you...
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data
- Have history of diabetes (except gestational diabetes) or current diagnosis of diabetes (any form), or have HbA1c greater than or equal to 6.5% (48 millimole per mole (mmol/mol)) at screening
- Are individuals of childbearing potential (IOCBP).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Collaborative Neuroscience Network - CNS
Los Alamitos, California, United States, 90720
Actively Recruiting
2
ICON Early Phase Services
San Antonio, Texas, United States, 78209
Actively Recruiting
3
Lilly Centre for Clinical Pharmacology
Singapore, Singapore, 138623
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
BASIC_SCIENCE
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here